COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,740 Articles (22,502 medRxiv, 8,238 bioRxiv)

Most recent first Previous |  Page 1492: Articles 14911-14920  | Next

Binding of SARS-CoV-2 fusion peptide to host membranes
Schaefer, S. L., Jung, H., Hummer, G.
10.1101/2021.05.10.443474 — Posted: 2021-05-10
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
Joyce, M. G., Modjarrad, K.
10.1101/2021.05.09.443331 — Posted: 2021-05-10 Discussion: Offsite
Nanopore dwell time analysis permits sequencing and conformational assignment of pseudouridine in SARS-CoV-2
Burrows, C. J., Mathewson, N. J., Fleming, A. M.
10.1101/2021.05.10.443494 — Posted: 2021-05-10
Rapid inactivation of SARS-CoV-2 variants by continuous and intermittent irradiation with a deep-ultraviolet light-emitting diode (DUV-LED) device
Inagaki, H., Saito, A., Kaneko, C., Sugiyama, H., Okabayashi, T., Fujimoto, S.
10.1101/2021.05.10.443422 — Posted: 2021-05-10
SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1
Law, J. L. M., Logan, M., Joyce, M., Landi, A., Hockman, D., Crawford, K., Johnson, J., LaChance, G., Saffran, H., Shields, J., Hobart, E., Brassard, R., Arutyunova, E., Pabbaraju, K., Croxen, M., Tipples, G., Lemieux, M. J., Tyrrell, D. L., Houghton, M.
10.1101/2021.05.10.443438 — Posted: 2021-05-10
High Dose Convalescent Plasma in COVID-19: Results from the randomized Trial CAPSID
Koerper, S., Weiss, M., Zickler, D., Wiesmann, T., Zacharowski, K., Corman, V. M., Gruener, B., Ernst, L., Spieth, P., Lepper, P. M., Bentz, M., Zinn, S., Paul, G., Kalbhenn, J., Dollinger, M., Rosenberger, P., Kirschning, T., Thiele, T., Appl, T., Mayer, B., Schmidt, M., Drosten, C., Wulf, H., Kruse, J. M., Jungwirth, B., Seifried, E., Schrezenmeier, H.
10.1101/2021.05.10.21256192 — Posted: 2021-05-10
A population-level analysis of the protective effects of androgen deprivation therapy against COVID-19 disease incidence and severity
Lee, K., Heberer, K., Gao, A., Becker, D. J., Loeb, S., Makarov, D., Gulanski, B., Duvall, S., Aslan, M., Lee, J., Hauger, R., Shih, M.-C., Lynch, J., Rettig, M.
10.1101/2021.05.10.21255146 — Posted: 2021-05-10 Discussion: Onsite
A quantitative risk-benefit analysis of ChAdOx1 nCoV-19 vaccine among people under 60 in Italy
Palladino, R., Ceriotti, D., De Ambrosi, D., De Vito, M., Farsoni, M., Seminara, G., Barone-Adesi, F.
10.1101/2021.05.07.21256826 — Posted: 2021-05-10
SARS-CoV-2 Heterogeneity by Ethnicity in Los Angeles
Allan-Blitz, L.-T., Hertlein, F., Klausner, J. D.
10.1101/2021.05.10.21256955 — Posted: 2021-05-10
Characterizing cellular and molecular variabilities of peripheral immune cells in healthy inactivated SARS-CoV-2 vaccine recipients by single-cell RNA sequencing
Tong, R., Zhong, J., Li, R., Chen, Y., Hu, L., Li, Z., Shi, J., Lin, G., Lyu, Y., Hu, L., Guo, X., Liu, Q., Shuang, T., Zhang, C., Yuan, A., Zhang, M., Lin, W., Pu, J.
10.1101/2021.05.06.21256781 — Posted: 2021-05-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).